Fludarabine

BreastfeedingPediatric
  • TRADE NAMES: Fludara (Genzyme); Oforta (Sanofi-Aventis)
  • INDICATIONS: Chronic lymphocytic leukemia (B-cell)
  • CLASS: Antimetabolite, Antineoplastic
  • HALF-LIFE: 9 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aldesleukin, Clofazimine, Live vaccines, Pentostatin

PREGNANCY CATEGORY: D

Severe neurologic effects, including blindness, coma, and death were observed in dose-ranging studies in patients with acute leukemia when fludarabine phosphate was administered at high doses.

Instances of life-threatening and sometimes fatal autoimmune hemolytic anemia have been reported after one or more cycles of treatment with fludarabine phosphate.

CNS TOXICITY, HEMOLYTIC ANEMIA, AND PULMONARY TOXICITY

See full prescribing information for complete boxed warning.

Our database has 114 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
HEMATOLOGIC
OTIC
OCULAR
LOCAL
OTHER


Page last updated 08/21/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric